Press release
Frontotemporal Dementia Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers
Discover the latest drugs and treatment options in the Frontotemporal Dementia Pipeline. Dive into DelveInsight's comprehensive report today! @ Frontotemporal Dementia Pipeline Outlook [https://www.delveinsight.com/sample-request/frontotemporal-dementia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Frontotemporal Dementia Pipeline Report
* In October 2024:- Sanofi- To assess prevalence of Gaucher disease (GD) diagnosed in pediatric patients presenting with unexplained splenomegaly (SMG) after exclusion of first intention-diagnoses (e.g. portal hypertension, haematological malignancy, hemolytic anemia, infection) based on clinical examination and routine biological tests (full blood count, reticulocytes, liver tests, abdominal ultrasound, Coombs test and Epstein Barr virus serology).
* DelveInsight's Frontotemporal Dementia pipeline report depicts a robust space with 15+ active players working to develop 20+ pipeline therapies for Frontotemporal Dementia treatment.
* The leading Frontotemporal Dementia Companies such as Transposon Therapeutics, Alector, Vesper Bio, AviadoBio, Passage Bio, Eli Lilly and Company, Coya Therapeutics, Neurimmune Therapeutics, Asceneuron SA., and others
* Promising Frontotemporal Dementia Therapies such as LY3884963, DNL593, AL001, PBFT02. Olipudase alfa, and others
Stay ahead with the most recent pipeline outlook for Frontotemporal Dementia. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Frontotemporal Dementia Treatment Drugs [https://www.delveinsight.com/sample-request/frontotemporal-dementia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Frontotemporal Dementia Emerging Drugs Profile
* AL001: Alector
AL001 is a recombinant human anti-human sortilin (SORT1) monoclonal IgG1 developed by Alector in partnership with GSK. It aims to increase the level of progranulin in humans by inhibiting a progranulin degradation mechanism. The antibody received orphan drug designation, fast track designation, and breakthrough designation from the US FDA for the treatment of frontotemporal dementia. Alector Inc. is currently investigating AL001 in Phase III clinical trials for FTD with a C9orf72 mutation and granulin mutation.
* TPN-101: Transposon Therapeutics
TPN-101 specifically inhibits the LINE-1 reverse transcriptase that promotes LINE-1 replication. LINE-1 elements are a class of retrotransposable elements that in humans are uniquely capable of replicating and moving to new locations within the genome. When this process becomes dysregulated, LINE-1 reverse transcriptase drives overproduction of LINE-1 DNA, triggering innate immune responses that contribute to neurodegenerative, autoimmune and aging-related disease pathology. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of Frontotemporal Dementia.
* AVB-101: AviadoBio
AVB-101 is a potential one-time therapy designed to stop disease progression by delivering a functional copy of the GRN gene to restore appropriate progranulin levels to affected areas of the brain. The drug is delivered using a minimally invasive, stereotactic neurosurgical procedure directly to the part of the brain called the thalamus. The thalamus has extensive connections to other parts of the brain, including the frontal and temporal lobes, which play a critical role in FTD and the symptoms that impact patients and their families. This targeted delivery method aims to safely and effectively cross the blood-brain barrier, delivering targeted treatment directly to the brain to restore progranulin levels in the frontal and temporal cortex where it is needed most, while at the same time minimizing the dose required and thereby limiting any potential systemic exposure. In November 2023, the US Food and Drug Administration (FDA) granted Fast Track designation to AVB-101. Currently, the drug is being evaluated in the Phase I/II stage of its development for the treatment of Frontotemporal Dementia.
* VES001: Vesper Bio
VES001 is the first oral, brain penetrant, small molecule sortilin inhibitor designed as a potentially disease-modifying treatment for the neuro-cognitive disorder fronto-temporal dementia (FTD (GRN)). Data returned from this study (NCT06226064) demonstrate the safety and tolerability of VES001 across the full range of doses tested and show it has excellent pharmacokinetics and distribution to relevant parts of the brain. The data predict a once or twice daily efficacious dose. Importantly, volunteers who received VES001 experienced significant and robust increases in levels of progranulin, demonstrating target engagement. Progranulin is a protein known to play a key role in promoting neuron survival, growth and function. People with FTD(GRN) have inherited gene mutations associated with low progranulin levels.
Explore groundbreaking therapies and clinical trials in the Frontotemporal Dementia Pipeline. Access DelveInsight's detailed report now! @ New Frontotemporal Dementia Drugs [https://www.delveinsight.com/sample-request/frontotemporal-dementia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Frontotemporal Dementia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration
* Intra-articular
* Intraocular
* Intrathecal
* Intravenous
* Ophthalmic
* Oral
* Parenteral
* Subcutaneous
* Topical
* Transdermal
Frontotemporal Dementia Products have been categorized under various Molecule types such as
* Oligonucleotide
* Peptide
* Small molecule
Unveil the future of Frontotemporal Dementia Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Frontotemporal Dementia Market Drivers and Barriers [https://www.delveinsight.com/sample-request/frontotemporal-dementia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Frontotemporal Dementia Pipeline Report
* Coverage- Global
* Frontotemporal Dementia Companies- Transposon Therapeutics, Alector, Vesper Bio, AviadoBio, Passage Bio, Eli Lilly and Company, Coya Therapeutics, Neurimmune Therapeutics, Asceneuron SA., and others.
* Frontotemporal Dementia Therapies- LY3884963, DNL593, AL001, PBFT02. Olipudase alfa, and others
* Frontotemporal Dementia Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Frontotemporal Dementia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Get the latest on Frontotemporal Dementia Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Frontotemporal Dementia Companies, Key Products and Unmet Needs [https://www.delveinsight.com/sample-request/frontotemporal-dementia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* Frontotemporal Dementia: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Frontotemporal Dementia- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Latozinemab: Alector
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Drug Name: Company Name
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I/II)
* PR 006 : Prevail Therapeutics
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* EXO-050: Coya Therapeutics
* Drug profiles in the detailed report.....
* Inactive Products
* Frontotemporal Dementia Key Companies
* Frontotemporal Dementia Key Products
* Frontotemporal Dementia- Unmet Needs
* Frontotemporal Dementia- Market Drivers and Barriers
* Frontotemporal Dementia- Future Perspectives and Conclusion
* Frontotemporal Dementia Analyst Views
* Frontotemporal Dementia Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=frontotemporal-dementia-pipeline-therapeutics-assessment-companies-products-unmet-needs-market-drivers-and-barriers]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Frontotemporal Dementia Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers here
News-ID: 3692174 • Views: …
More Releases from ABNewswire
Reliable Roof Repair in Poughkeepsie, NY: GKontos Roofing & Exterior Specialists …
When homes or businesses in Poughkeepsie face roof damage, it often requires immediate attention to prevent costly structural issues. From minor leaks to storm damage, GKontos Roofing & Exterior Specialists has built a reputation in the Hudson Valley for dependable roof repair services that prioritize both quality and long-term protection. With decades of experience and a focus on serving local communities, the company continues to be a trusted name for…
Professional Service Standards for Garage Doors in Rhode Island Rise with Patrio …
Patriots Overhead serves 50+ Rhode Island and Massachusetts communities with A+ BBB-rated garage door repair and installation. Veteran-owned, offering 10% discounts to first responders and military personnel.
Rhode Island homeowners and businesses now have access to enhanced garage door services as Patriots Overhead [https://www.google.com/maps/place/Patriots+Overhead/data=!4m2!3m1!1s0x0:0x928a9199ffcee4f7?sa=X&ved=1t:2428&hl=en&ictx=111] continues building its reputation across the region. Founded in 2014 by Isaac and Tyler, the company has grown from a two-person operation to a trusted name serving…
EarnBill Unveils Future Trends in Telecom Billing: What's Next for Billing Softw …
Image: https://www.abnewswire.com/upload/2025/10/9f68f2930db87f7692cb100cfff4eeb6.jpg
Before understanding the expected changes in the coming years for telecom billing software, let's understand how Telecom Billing Systems [https://earnbill.com/telecom-billing/] have evolved so far.
Legacy Systems (Pre-2000s)
Manual & Batch Processing: Billing was periodic, and there was one flat price for the plan.
Less Flexible: With very little or no capability for value-added offerings, it was essentially voice.
Maintenance: These were custom-built systems and thus difficult to upgrade.
Converged Billing (2000s-2010s)
Integrates Voice, Data, SMS:…
What is a NOC vs SOC? Pennsylvania Commercial IT Support Providers Address Criti …
Allentown technology experts clarify NOC versus SOC distinctions as Pennsylvania businesses face a 47% annual increase in cyber incidents, driving demand for integrated managed services.
ALLENTOWN, PA - As cybersecurity incidents across Pennsylvania increase by 47% annually, technology professionals are clarifying fundamental distinctions between Network Operations Centers (NOCs) and Security Operations Centers (SOCs) for business leaders evaluating protection strategies. Epoch IT Services, headquartered in Allentown with additional operations in Vermont, reports…
More Releases for Frontotemporal
Frontotemporal Dementia (FTD) Market to Reach USD 4.3 Billion by 2034
Frontotemporal Dementia (FTD) is a rare yet serious group of neurodegenerative disorders characterized by progressive damage to the frontal and temporal lobes of the brain. Unlike Alzheimer's disease, FTD often manifests earlier in life, typically between the ages of 40 and 65, and is marked by personality changes, impaired judgment, and language difficulties. Its early onset and challenging diagnosis make it one of the most complex forms of dementia to…
Frontotemporal Dementia Market Set to Double by 2034, Reaching USD 4.2 Billion
The global FTD market was valued at USD 2.1 billion in 2024 and is projected to reach USD 4.2 billion by 2034, growing at a CAGR of 7.1%. Rising diagnosis rates, growing investment in neurodegenerative disease research, and expanded healthcare access are driving this growth.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/70788
Key Market Highlights
• Increasing recognition of FTD as distinct from Alzheimer's and other dementias.
• Expanding pipeline of clinical trials…
Frontotemporal Dementia Treatment Market - Empathy in Action: Pioneering Frontot …
Newark, New Castle, USA: The "Frontotemporal Dementia Treatment Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Frontotemporal Dementia Treatment Market: https://www.growthplusreports.com/report/frontotemporal-dementia-treatment-market/8569
This latest report researches the industry structure,…
Frontotemporal Dementia Treatment Market Insights Deep Analysis 2023-2031
Cognate Life Sciences introduces a report on "Frontotemporal Dementia Treatment Market 2023" with Market Insights Reports, Introduces systematic details in terms of market valuation, market size, revenue estimation, and geographical spectrum of the business vertical. The study also talks about crucial pockets of the industry such as products or services offered, downstream fields, end using customers, historic data figures regarding revenue and sales, market context and more. It conjointly studies…
Frontotemporal Disorder Treatment Market Size, Share, Impressive Industry Growth …
The global Frontotemporal Disorder treatment market is anticipated to showcase considerable growth during the forecast period (2020-2026). The rising orphan drug development initiatives by the FDA, new product launches and the growing geriatric population are some of the key factors contributing to the growth of the global Frontotemporal Disorder treatment market. According to the World Health Organization, in 2019 around 50 million people are living with dementia and the number…
Improvement In Cognitive Empathy to Drive The Frontotemporal Dementia Treatment …
The global Frontotemporal Dementia Treatment Market is bound to witness a CAGR worth satiating In Upcoming Years. In the era of cloud computing, the cloud revolution is there to break the stereotypes. Several key stakeholders are going for cloud hosting solutions providers to enhance their accounting services. This migration to cloud technology is making way for the enterprises to simplify their daily tasks, that too, conveniently and cost-effectively. As such,…
